Member Info for moonparty

Honestly, Rishi has zero chance of getting elected so IHT is going to stay for now.

This whole thread is moot!

- Sells outweighed buys the last couple of days and the price has held up.

- I have been able to sell between 200 and 300k shares on auto (checked a few times).

- Usual trader nonsense doesn't seem to be working to force a retrace.

Obviously I didn't sell, that would be foolish, my target is much, much higher!

Dracula, as I understand it, back in the day, Scancell had a buyer lined up for SCIB1 but they pulled out last minute due to one/several industry failures in cancer vaccines, and a corresponding change in investor sentiment towards them.

We are in a very different place now in terms of both sentiment (vaccines very much riding the zeitgeist) and product (more excellent data, needle free, iscib1+ will work in the entire population not just 30%).

So, I would expect there is massive interest currently, and definitely not expecting a repeat of the last SCIB1 trial investor outcome.

I can understand investor reticence after so many false starts, but I think we are most definitely "nearly there" now.

In fact, the game should change from "are we nearly there yet" to "prize for the first to see the sea" :)

Roses, Scancell could licence the product for specific indications also and enable several pharmas to extend their future range in their chosen area.

Looks like someone has a large buy order in for 16p?

It's all there:

- the science

- the data backing up the science

- a more investor-friendly approach to RNS and investor comms

- the right balance of technical: business people in the Scancell team

I can't see any reason this won't continue to rise - there are a whole load more people aware of Scancell than there were 2 days ago who will be researching as we speak, most of toe 10% traders will be long gone after today, and weak holders have already left.

Well done all who held strong.

Good point, well made :)

Obviously took the MM's by surprise as well, as they have now raised the spread to protect themselves.

Scancell has historically been a very tight ship, so I wouldn't have thought a leak is likely.

However, with current sentiment I could not have predicted this rise. Pre-conference hype is NEVER like this, especially with current climate.

At a loss to explain it tbh, but very welcome. And IMO, extremely minor compare to where the sp should be.

I would much rather read industry-relevant posts than posts from people who simply criticise others without offering any original thought or content. Or people with pretty transparent ulterior motives.

Personally I enjoy clenerworlds posts (please keep posting), and I don't think it's appropriate for anyone to try and bully or censor other contributors, especially well-behaved and polite ones.

Bobbust, agree 100% - pretty sure it's been discussed here before, but it will be so much easier to do a combo-with-CPI deal than a mono-therapy deal.

The RNS releases are sounding much more confident, very good sign!

Good spot Bazookajr, seems covidity is still a valuable asset.

As ever, everyone is just talking their book.

Obviously crumbs and Bermuda have reduced/zero holdings and possibly looking to get back in, so want the price lower. Even if they are not looking to buy back, it's psychologically important to back up their decision.

AB124 just like's to wind people up, nothing better to do.

It's all very positive for me - crumbs, "one partial response" is nonsense, recent RNS stated 44% disease control rate in Ovarian cancer on mono-therapy alone, CPI results yet to come but will almost certainly be better. Sounds pretty commercial to me, especially for poor souls who have zero other options.

Anyway, this board seems to have gone horribly toxic. Probably best ignored for now, and those that still have an interest wait for the next few RNSs - imo, this is still the best risk/reward play you are likely to find. But what do I know, I am an idiot long term shareholder with confirmation bias.

It's clearly an arranged transfer between 2 accounts or 2 related parties. The proximity of the trade, the small difference in price and the fact it had no effect on the quoted price tells us this.

And I suppose LD is well known enough in the industry that potential suitors know she will not entertain silly offers of less than £8 a share, so they are all waiting for the data :)

Then let the mad scramble begin!

The point has been made many times here, and several times by Scancell themselves, that to do the best deal, we need data - preclinical data will get you so far - I am 99.9% sure informal offers on preclinical data have been available that weren't considered good enough. Clinical trial data is the gold standard to get a deal that truly rewards the science, the scientists and the LTH.

And that is what Scancell are doing.

C11 that's hilarious, made me laugh out loud :)

Now now C11, you'll get accused of ramping!

I thought the whole of Scancell was £8 a share, if Glymab alone is £8, then the whole of Scancell is, what, £32?

Funny that the sentiment-shifters appear to try and drop the price, then a week or 2 later the tip-sheets start getting bullish.

Almost as though they are working in cahoots with each other, but of course this is just my opinion.

MM games - a small UT trade went through for 100 shares (grand sum of £9.50). Irrelevant, but LSE seems to take mid price from the last UT until the quoted NMS price changes.

Sorry to see you exit the share C7, I have always enjoyed your contributions and respect you as a poster.

I hope the next few weeks will give you the confidence to buy back, but wish you well either way.